Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
* Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
* Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
* Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
* Hypercalcemia associated with cancer
Rheumatic Disorders
=====Rheumatic Disorders=====
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in:
* As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in the following conditions
Psoriatic arthritis
:* Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
:* Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
:* Ankylosing spondylitis
Acute and subacute bursitis
:* Acute and subacute bursitis
Acute nonspecific tenosynovitis
:* Acute nonspecific tenosynovitis
Acute gouty arthritis
:* Acute gouty arthritis
Post-traumatic osteoarthritis
:* Post-traumatic osteoarthritis
Synovitis of osteoarthritis
:* Synovitis of osteoarthritis
Epicondylitis
:* Epicondylitis
Collagen Diseases
=====Collagen Diseases=====
During an exacerbation or as maintenance therapy in selected cases of:
* During an exacerbation or as maintenance therapy in selected cases of following conditions.
Systemic lupus erythematosus
:* Systemic lupus erythematosus
Acute rheumatic carditis
:* Acute rheumatic carditis
Systemic dermatomyositis (polymyositis)
:* Systemic dermatomyositis (polymyositis)
Dermatologic Diseases
:* Dermatologic Diseases
Pemphigus
:* Pemphigus
Bullous dermatitis herpetiformis
:* Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
:* Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
:* Exfoliative dermatitis
Mycosis fungoides
:* Mycosis fungoides
Severe psoriasis
:* Severe psoriasis
Severe seborrheic dermatitis
:* Severe seborrheic dermatitis
Allergic States
=====Allergic States=====
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment:
* Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment of following conditions.
Seasonal or perennial allergic rhinitis
:* Seasonal or perennial allergic rhinitis
Bronchial asthma
:* Bronchial asthma
Contact dermatitis
:* Contact dermatitis
Atopic dermatitis
:* Atopic dermatitis
Serum sickness
:* Serum sickness
Drug hypersensitivity reactions
:* Drug hypersensitivity reactions
Ophthalmic Diseases
=====Ophthalmic Diseases=====
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
* Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
Allergic conjunctivitis
* Allergic conjunctivitis
Keratitis
* Keratitis
Allergic corneal marginal ulcers
* Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
* Herpes zoster ophthalmicus
Iritis and iridocyclitis
* Iritis and iridocyclitis
Chorioretinitis
* Chorioretinitis
Anterior segment inflammation
* Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
* Diffuse posterior uveitis and choroiditis
Optic neuritis
* Optic neuritis
Sympathetic ophthalmia
* Sympathetic ophthalmia
Respiratory Diseases
* Respiratory Diseases
Symptomatic sarcoidosis
* Symptomatic sarcoidosis
Loeffler's syndrome not manageable by other means
* Loeffler's syndrome not manageable by other means
Berylliosis
* Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy
* Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy
Aspiration pneumonitis
* Aspiration pneumonitis
Hematologic Disorders
=====Hematologic Disorders=====
Idiopathic thrombocytopenic purpura in adults
* Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
* Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
* Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
* Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
* Congenital (erythroid) hypoplastic anemia
Neoplastic Diseases
=====Neoplastic Diseases=====
For palliative management of:
* For palliative management of following conditions.
Leukemias and lymphomas in adults
:* Leukemias and lymphomas in adults
Acute leukemia of childhood
:* Acute leukemia of childhood
Edematous States
:* Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
:* To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
Gastrointestinal Diseases
=====Gastrointestinal Diseases=====
To tide the patient over a critical period of the disease in:
* To tide the patient over a critical period of the disease in the follwoing conditions.
Ulcerative colitis
:* Ulcerative colitis
Regional enteritis
:* Regional enteritis
Miscellaneous
=====Miscellaneous=====
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
* Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement.
* Trichinosis with neurologic or myocardial involvement.
For Oral Administration
====For Oral Administration=====
* DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.
DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.
* The initial dosage varies from 25 to 300 mg a day depending on the disease being treated. In less severe diseases doses lower than 25 mg may suffice, while in severe diseases doses higher than 300 mg may be required. The initial dosage should be maintained or adjusted until the patient's response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue cortisone acetate tablets and transfer the patient to other therapy.
* After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
The initial dosage varies from 25 to 300 mg a day depending on the disease being treated. In less severe diseases doses lower than 25 mg may suffice, while in severe diseases doses higher than 300 mg may be required. The initial dosage should be maintained or adjusted until the patient's response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue cortisone acetate tablets and transfer the patient to other therapy.
* Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.
* If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.
After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
|offLabelAdultGuideSupport=
Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.
If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.
|offLabelAdultGuideSupport======Condition1=====
* Developed by:
* Class of Recommendation:
* Strength of Evidence:
* Dosing Information
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport=* Carcinoma of breast
|offLabelAdultNoGuideSupport======Condition1=====
* Carcinoma of prostate
* Fever, due to malignancy; treatment adjunct
* Dosing Information
* Intracranial tumor
* Multiple myeloma
:* Dosage
=====Condition2=====
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
<!--Pediatric Indications and Dosage-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance).
Congenital adrenal hyperplasia
Nonsuppurative thyroiditis
Hypercalcemia associated with cancer
Rheumatic Disorders
As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in the following conditions
Psoriatic arthritis
Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy)
Ankylosing spondylitis
Acute and subacute bursitis
Acute nonspecific tenosynovitis
Acute gouty arthritis
Post-traumatic osteoarthritis
Synovitis of osteoarthritis
Epicondylitis
Collagen Diseases
During an exacerbation or as maintenance therapy in selected cases of following conditions.
Systemic lupus erythematosus
Acute rheumatic carditis
Systemic dermatomyositis (polymyositis)
Dermatologic Diseases
Pemphigus
Bullous dermatitis herpetiformis
Severe erythema multiforme (Stevens-Johnson syndrome)
Exfoliative dermatitis
Mycosis fungoides
Severe psoriasis
Severe seborrheic dermatitis
Allergic States
Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment of following conditions.
Seasonal or perennial allergic rhinitis
Bronchial asthma
Contact dermatitis
Atopic dermatitis
Serum sickness
Drug hypersensitivity reactions
Ophthalmic Diseases
Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as:
Allergic conjunctivitis
Keratitis
Allergic corneal marginal ulcers
Herpes zoster ophthalmicus
Iritis and iridocyclitis
Chorioretinitis
Anterior segment inflammation
Diffuse posterior uveitis and choroiditis
Optic neuritis
Sympathetic ophthalmia
Respiratory Diseases
Symptomatic sarcoidosis
Loeffler's syndrome not manageable by other means
Berylliosis
Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy
Aspiration pneumonitis
Hematologic Disorders
Idiopathic thrombocytopenic purpura in adults
Secondary thrombocytopenia in adults
Acquired (autoimmune) hemolytic anemia
Erythroblastopenia (RBC anemia)
Congenital (erythroid) hypoplastic anemia
Neoplastic Diseases
For palliative management of following conditions.
Leukemias and lymphomas in adults
Acute leukemia of childhood
Edematous States
To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus
Gastrointestinal Diseases
To tide the patient over a critical period of the disease in the follwoing conditions.
Ulcerative colitis
Regional enteritis
Miscellaneous
Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy
Trichinosis with neurologic or myocardial involvement.
For Oral Administration=
DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE AND THE RESPONSE OF THE PATIENT.
The initial dosage varies from 25 to 300 mg a day depending on the disease being treated. In less severe diseases doses lower than 25 mg may suffice, while in severe diseases doses higher than 300 mg may be required. The initial dosage should be maintained or adjusted until the patient's response is satisfactory. If satisfactory clinical response does not occur after a reasonable period of time, discontinue cortisone acetate tablets and transfer the patient to other therapy.
After a favorable initial response, the proper maintenance dosage should be determined by decreasing the initial dosage in small amounts to the lowest dosage that maintains an adequate clinical response.
Patients should be observed closely for signs that might require dosage adjustment, including changes in clinical status resulting from remissions or exacerbations of the disease, individual drug responsiveness, and the effect of stress (e.g., surgery, infection, trauma). During stress it may be necessary to increase dosage temporarily.
If the drug is to be stopped after more than a few days of treatment, it usually should be withdrawn gradually.
Off-Label Use and Dosage (Adult)
Guideline-Supported Use
There is limited information regarding Off-Label Guideline-Supported Use of Cortisone in adult patients.
Non–Guideline-Supported Use
Carcinoma of breast
Carcinoma of prostate
Fever, due to malignancy; treatment adjunct
Intracranial tumor
Multiple myeloma
Pediatric Indications and Dosage
FDA-Labeled Indications and Dosage (Pediatric)
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding FDA-Labeled Use of Cortisone in pediatric patients.
Off-Label Use and Dosage (Pediatric)
Guideline-Supported Use
Condition1
Developed by:
Class of Recommendation:
Strength of Evidence:
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Guideline-Supported Use of Cortisone in pediatric patients.
Non–Guideline-Supported Use
Condition1
Dosing Information
Dosage
Condition2
There is limited information regarding Off-Label Non–Guideline-Supported Use of Cortisone in pediatric patients.
Contraindications
Condition1
Warnings
Description
Precautions
Description
Adverse Reactions
Clinical Trials Experience
There is limited information regarding Clinical Trial Experience of Cortisone in the drug label.
Body as a Whole
Cardiovascular
Digestive
Endocrine
Hematologic and Lymphatic
Metabolic and Nutritional
Musculoskeletal
Neurologic
Respiratory
Skin and Hypersensitivy Reactions
Special Senses
Urogenital
Miscellaneous
Postmarketing Experience
There is limited information regarding Postmarketing Experience of Cortisone in the drug label.
